Leonteq Securities AG’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Leonteq Securities AG’s Portfolio CERE Stock Details CERE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-404	Closed	-$9.85K	–	1331
2023 Q1	$9.85K	Sell	404 -33	-8%	-$969	﹤0.01%	1030
2022 Q4	$13.8K	Sell	437 -35	-7%	-$988	﹤0.01%	1018
2022 Q3	$13.3K	Hold	472	–	–	﹤0.01%	1016
2022 Q2	$12.5K	Sell	472 -49	-9%	-$1.39K	﹤0.01%	1052
2022 Q1	$18.2K	Hold	521	–	–	﹤0.01%	1017
2021 Q4	$16.9K	Buy	+521	New	+$18.4K	﹤0.01%	1078

Other funds holding CERE

BCI

Bain Capital Investors Boston, Massachusetts $3.27B AUM 3.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Leonteq Securities AG's CERE Position: Q2 2023 in Review

Leonteq Securities AG sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q2 2023, closing a stake of 404 shares — an estimated $9.85K sold.

Leonteq Securities AG first reported a position in CERE in Q4 2021 and held it in 6 quarters. The position peaked at $18.2K in Q1 2022. 125 funds tracked by Wall St. Rank hold CERE as of Q2 2023.

Leonteq Securities AG reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Leonteq Securities AG sold 404 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q2 2023, an estimated $9.85K.
Leonteq Securities AG first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2021 and held it in 6 quarters.
Leonteq Securities AG's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $18.2K in Q1 2022.
125 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q2 2023.

Based on Leonteq Securities AG's 13F filing for Q2 2023, filed 11 Mar 2026.